|
| 36097168 | Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy. | Prostate Cancer Prostatic Dis | 2024 |
| 38010955 | Point of View: Innovation and Progress for Screening and Management of Localized Prostate Cancer: What an Exciting Time. | J Urol | 2024 |
| 36756801 | National Trends in the Practice of Active Surveillance. | J Urol | 2023 |
| 37865044 | Clinical consequences of a genetic predisposition toward higher benign prostate-specific antigen levels. | EBioMedicine | 2023 |
| 37126312 | Point-Counterpoint: Clinical Pragmatism Should Prevail Over Biological Orthodoxy: "Pro" Perspective. | J Urol | 2023 |
| 37010836 | Use of Active Surveillance vs Definitive Treatment Among Men With Low- and Favorable Intermediate-Risk Prostate Cancer in the US Between 2010 and 2018. | JAMA Intern Med | 2023 |
| 36973367 | Optimizing detection of clinically significant prostate cancer through nomograms incorporating mri, clinical features, and advanced serum biomarkers in biopsy naïve men. | Prostate Cancer Prostatic Dis | 2023 |
| 37103448 | Editorial Commentary. | Urol Pract | 2023 |
| 37102722 | Editorial Comment. | J Urol | 2023 |
| 36585434 | MyProstateScore in men considering repeat biopsy: validation of a simple testing approach. | Prostate Cancer Prostatic Dis | 2023 |
| 36877498 | A Polygenic Risk Score for Prostate Cancer Risk Prediction. | JAMA Intern Med | 2023 |
| 36424086 | Combined Use of Magnetic Resonance Imaging and Biomarker Testing to Detect Clinically Significant Prostate Cancer. | Urol Clin North Am | 2023 |
| 34285350 | Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative. | Prostate Cancer Prostatic Dis | 2022 |
| 35798854 | The evolving clinical use of prostate cancer biomarkers. | Prostate Cancer Prostatic Dis | 2022 |
| 35472327 | Prostate Cancer With Peritoneal Carcinomatosis: A Robotic-assisted Radical Prostatectomy-based Case Series. | Urology | 2022 |
| 35695902 | Editorial Comment. | J Urol | 2022 |
| 35934625 | Active Surveillance for Intermediate-risk Prostate Cancer: A Systematic Review, Meta-analysis, and Metaregression. | Eur Urol Oncol | 2022 |
| 35947808 | Editorial Comment. | J Urol | 2022 |
| 33812851 | Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer. | Eur Urol Oncol | 2022 |
| 34937406 | Editorial Comment. | J Urol | 2022 |
| 34906585 | Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need. | Urology | 2022 |
| 35110702 | Awaiting the perfect diagnostic test: optimal prostate cancer care begins without a diagnosis. | Prostate Cancer Prostatic Dis | 2022 |
| 35050303 | Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts. | JAMA Oncol | 2022 |
| 34753659 | Association of MyProstateScore (MPS) with prostate cancer grade in the radical prostatectomy specimen. | Urol Oncol | 2022 |
| 34689607 | Editorial Comment. | J Urol | 2022 |
| 32631746 | Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study. | Eur Urol | 2021 |
| 33721334 | Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy. | Cancer | 2021 |
| 34902034 | Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. | JAMA Netw Open | 2021 |
| 34412509 | Editorial Comment. | J Urol | 2021 |
| 34430413 | Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions. | Transl Androl Urol | 2021 |
| 33985797 | Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. | Eur Urol | 2021 |
| 34062284 | Assessment of MYC/PTEN Status by Gene-Protein Assay in Grade Group 2 Prostate Biopsies. | J Mol Diagn | 2021 |
| 34288719 | Testing-Related Health Impact of Transrectal and Transperineal Prostate Biopsy as Assessed by Health Utilities. | J Urol | 2021 |
| 34337549 | Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [<sup>177</sup>Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer. | Eur Urol Open Sci | 2021 |
| 34337531 | Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study. | Eur Urol Open Sci | 2021 |
| 34196715 | Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. | JAMA Netw Open | 2021 |
| 34137274 | Editorial Comment. | J Urol | 2021 |
| 33080150 | Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach. | J Urol | 2021 |
| 33471043 | Evaluation of Patient- and Surgeon-Specific Variations in Patient-Reported Urinary Outcomes 3 Months After Radical Prostatectomy From a Statewide Improvement Collaborative. | JAMA Surg | 2021 |
| 30992160 | Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. | Eur Urol | 2020 |
| 35050780 | Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. | JCO Precis Oncol | 2020 |
| 31969336 | <i>CDKN1B</i> Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer. | Clin Cancer Res | 2020 |
| 31951501 | Editorial Comment. | J Urol | 2020 |
| 32067844 | Do patients who undergo multiparametric MRI for prostate cancer benefit from additional staging imaging? Results from a statewide collaborative. | Urol Oncol | 2020 |
| 33272425 | EDITORIAL COMMENT. | Urology | 2020 |
| 33173205 | Surgical management of high-risk, localized prostate cancer. | Nat Rev Urol | 2020 |
| 32777370 | Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice. | Urology | 2020 |
| 32777369 | Overtreatment and Underutilization of Watchful Waiting in Men With Limited Life Expectancy: An Analysis of the Michigan Urological Surgery Improvement Collaborative Registry. | Urology | 2020 |
| 32943262 | Biopsy Cell Cycle Proliferation Score Predicts Adverse Surgical Pathology in Localized Renal Cell Carcinoma. | Eur Urol | 2020 |
| 32701384 | Editorial Comment. | J Urol | 2020 |